WeVote
Log In

Bill

Bill

A 6621

Relates to the sale of cannabinoid hemp products

2025 Regular Session Introduced by Keith Brown and 12 co-sponsors

Regulates the sale of cannabinoid hemp products by establishing licensing, labeling, testing, and enforcement to protect consumers and ensure product safety.

REFERRED TO ECONOMIC DEVELOPMENT
0
WeVote Research Nonpartisan
Bill Summary · A 6621

Summary of Bill A 6621: Relates to the sale of cannabinoid hemp products

Overview

Bill A 6621 is a New York Assembly measure titled “Relates to the sale of cannabinoid hemp products.” The bill, introduced on March 6, 2025, proposes to regulate the sale of cannabinoid hemp products. The bill has been referred to the Economic Development Committee and has a Senate companion identified as S 7130. The same referral action appears twice in the provided legislative actions.

Purpose and intent

  • Establish a regulatory framework governing the sale of cannabinoid hemp products.
  • Aim to address consumer safety, product integrity, and oversight of sellers within the marketplace.
  • Create or modify licensing, labeling, testing, and enforcement mechanisms to oversee the sale of these products.

Note: The actual text of the bill is not provided in the materials shared. The summary below reflects the bill’s likely focus based on its title and standard approaches used in similar legislation. Specific provisions, definitions, and requirements would be spelled out in the full bill text.

Key provisions (typical areas likely covered)

Because the bill’s full text is not included here, the following are common components of cannabinoid hemp product regulation that A 6621 may address:
- Definitions: Clear definitions of “cannabinoid hemp products,” allowable cannabinoids, product forms, and related terms.
- Licensing and registration: Requirements for retailers, distributors, and manufacturers to obtain licenses or permits to sell cannabinoid hemp products.
- Labeling and packaging: Standards for product labels, including ingredients, CBD/THC content, batch numbers, warnings, and allergen information.
- Testing and quality control: Mandatory third-party laboratory testing, acceptable potency ranges, contaminant limits (e.g., pesticides, heavy metals), and sampling procedures.
- Age and sale restrictions: Provisions on whether sales are restricted by age and any location-based restrictions.
- Advertising and marketing: Rules governing claims about health benefits or medical use.
- Enforcement and penalties: Sanctions for violations, including fines, license suspensions, and possible license revocation.
- Regulatory authority: Designation of the state department or agency responsible for implementation, inspections, and enforcement.
- Effective date and transition: When the rules take effect and any phase-in period for compliance.

Affected parties

  • Retailers and distributors selling cannabinoid hemp products.
  • Manufacturers and wholesalers of cannabinoid hemp products.
  • Consumers who purchase cannabinoid hemp products.
  • Regulatory agencies (likely the Department of Economic Development or a similar state agency) responsible for licensing, enforcement, and compliance.
  • Potential impact on local businesses and economic development related to hemp product markets.

Procedural history and timeline

  • Introduced: March 6, 2025.
  • Status: Referred to Economic Development (twice listed in the provided actions).
  • Related legislation: S 7130 is the Senate companion bill.
  • Next expected steps (not specified in the provided text): committee hearings and markups in Economic Development, approval by the chamber, potential floor vote, and passage to the other legislative chamber, followed by reconciliation with the Senate companion if differences arise.

Fiscal and policy considerations

  • Possible regulatory costs for the state to administer licensing, inspections, and enforcement.
  • Potential revenue from licensing fees or penalties.
  • Economic impact on retailers and manufacturers operating within the hemp product market.
  • Public health and consumer protection outcomes through standardized testing and labeling.

Notes

  • The exact provisions, definitions, and requirements will be detailed in the full bill text. This summary outlines the bill’s purpose and the typical regulatory areas such legislation tends to address, along with the known procedural context and related companion measure.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.